Is remylination being alleged? Or just fewer T1 and T2 lesions appearing per unit time? If the latter then there is a pathway to approval, but this biomarker has been shown (by Biogen itself, whose Avonex showed 98% reduction in lesions) not to actually correlate with disease progression.
News 
Market Data 
Discover 
AI
